'Oral anticoagulation' presentation slideshows

1.03k views • 74 slides

Improving the Outcomes of Oral Anticoagulation: Home Monitoring of Warfarin Therapy

Improving the Outcomes of Oral Anticoagulation: Home Monitoring of Warfarin Therapy. Jack Ansell, M.D. Lenox Hill Hospital, NY September 22, 2009. Disclosures Consultant: Roche Diagnostics, ITC, HemoSense. The Dilemma of Anticoagulation Management.

640 views • 44 slides

Ruben A. Mesa, MD, FACP

Case Study: A Y oung Patient with PV has a Major Thrombotic E vent and W orsening Leukocytosis - Is she Progressing to Post-PV MF?. Ruben A. Mesa, MD, FACP Chair, Division of Hematology & Medical Oncology Deputy Director, Mayo Clinic Cancer Center Professor of Medicine. Co-Presenters.

695 views • 41 slides

661 views • 40 slides

INTRODUCTION (1)

Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. INTRODUCTION (1). Fibrinolytic Therapy

377 views • 25 slides

Informing Patients about Their Medications Oral Anticoagulation Therapy

Informing Patients about Their Medications Oral Anticoagulation Therapy. Objectives. By the end of this session you should: Know why it is important to inform patients about their medicines Know what points to cover when newly prescribing a patient an oral anticoagulant.

479 views • 21 slides

Disclosures

Outcomes of Temporary Interruption of Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation.

326 views • 20 slides

LAA Closure: Beyond the Bleeding Patient Rahul N. Doshi, MD, FHRS, FACC

LAA Closure: Beyond the Bleeding Patient Rahul N. Doshi, MD, FHRS, FACC Director of Electrophysiology, CCEP Fellowship Director Associate Professor of Medicine Keck School of Medicine of USC, USC Cardiovascular Thoracic Institute, LAC + USC Medical Center. Relevant Disclosures.

1.09k views • 18 slides

Treatment and Secondary Prevention of Cancer-Associated Thrombosis

Treatment and Secondary Prevention of Cancer-Associated Thrombosis. Supplement to Module 6. Overview. Introduction UFH as initial treatment for VTE LMWH as initial treatment for VTE Fondaparinux as initial treatment for VTE Transition to long-term therapy with vitamin K antagonists

307 views • 17 slides

481 views • 13 slides